EC-18 for Management of Chemotherapy-Induced Neutropenia in Patients With Advanced BC Receiving Low Febrile Neutropenia Risk Chemotherapy: Dose-Escalation, Open-label, Trial to Assess Safety and Tolerability of EC-18

Trial Profile

EC-18 for Management of Chemotherapy-Induced Neutropenia in Patients With Advanced BC Receiving Low Febrile Neutropenia Risk Chemotherapy: Dose-Escalation, Open-label, Trial to Assess Safety and Tolerability of EC-18

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs EC 18 (Primary)
  • Indications Febrile neutropenia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Enzychem Lifesciences Corporation
  • Most Recent Events

    • 08 Aug 2017 Planned initiation date changed from 1 Jun 2017 to 1 Nov 2017.
    • 19 Jun 2017 Status changed from not yet recruiting to recruiting according to a Enzychem Lifesciences Corp. media release.
    • 01 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top